Corticosteroids compromise survival in glioblastoma

Kenneth L. Pitter, Ilaria Tamagno, Kristina Alikhanyan, Amira Hosni-Ahmed, Siobhan S. Pattwell, Shannon Donnola, Charles Dai, Tatsuya Ozawa, Maria Chang, Timothy A. Chan, Kathryn Beal, Andrew J. Bishop, Christopher A. Barker, Terreia S. Jones, Bettina Hentschel, Thierry Gorlia, Uwe Schlegel, Roger Stupp, Michael Weller, Eric C. Holland & 1 others Dolores Hambardzumyan

Research output: Research - peer-reviewArticle

  • 18 Citations

Abstract

Glioblastoma is the most common and most aggressive primary brain tumour. Standard of care consists of surgical resection followed by radiotherapy and concomitant and maintenance temozolomide (temozolomide/radiotherapy→temozolomide). Corticosteroids are commonly used perioperatively to control cerebral oedema and are frequently continued throughout subsequent treatment, notably radiotherapy, for amelioration of side effects. The effects of corticosteroids such as dexamethasone on cell growth in glioma models and on patient survival have remained controversial. We performed a retrospective analysis of glioblastoma patient cohorts to determine the prognostic role of steroid administration. A disease-relevant mouse model of glioblastoma was used to characterize the effects of dexamethasone on tumour cell proliferation and death, and to identify gene signatures associated with these effects. A murine anti-VEGFA antibody was used in parallel as an alternative for oedema control. We applied the dexamethasone-induced gene signature to The Cancer Genome Atlas glioblastoma dataset to explore the association of dexamethasone exposure with outcome. Mouse experiments were used to validate the effects of dexamethasone on survival in vivo. Retrospective clinical analyses identified corticosteroid use during radiotherapy as an independent indicator of shorter survival in three independent patient cohorts. A dexamethasone-associated gene expression signature correlated with shorter survival in The Cancer Genome Atlas patient dataset. In glioma-bearing mice, dexamethasone pretreatment decreased tumour cell proliferation without affecting tumour cell viability, but reduced survival when combined with radiotherapy. Conversely, anti-VEGFA antibody decreased proliferation and increased tumour cell death, but did not affect survival when combined with radiotherapy. Clinical and mouse experimental data suggest that corticosteroids may decrease the effectiveness of treatment and shorten survival in glioblastoma. Dexamethasone-induced anti-proliferative effects may confer protection from radiotherapy-and chemotherapy-induced genotoxic stress. This study highlights the importance of identifying alternative agents such as vascular endothelial growth factor antagonists for managing oedema in glioblastoma patients. Beyond the established adverse effect profile of protracted corticosteroid use, this analysis substantiates the request for prudent and restricted use of corticosteroids in glioblastoma.

LanguageEnglish (US)
Pages1458-1471
Number of pages14
JournalBrain
Volume139
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Glioblastoma
Dexamethasone
Adrenal Cortex Hormones
Survival
Radiotherapy
Compromise
Neoplasms
Cells
Mouse
Signature
temozolomide
Gene
Cohort
Atlas
Genome
Cancer
Atlases
Glioma
Anti-Idiotypic Antibodies
Edema

Keywords

  • astrocytoma
  • CNS tumour: surgical treatment
  • genetics
  • glioma
  • neurooncology

ASJC Scopus subject areas

  • Medicine(all)
  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Pitter, K. L., Tamagno, I., Alikhanyan, K., Hosni-Ahmed, A., Pattwell, S. S., Donnola, S., ... Hambardzumyan, D. (2016). Corticosteroids compromise survival in glioblastoma. Brain, 139(5), 1458-1471. DOI: 10.1093/brain/aww046

Corticosteroids compromise survival in glioblastoma. / Pitter, Kenneth L.; Tamagno, Ilaria; Alikhanyan, Kristina; Hosni-Ahmed, Amira; Pattwell, Siobhan S.; Donnola, Shannon; Dai, Charles; Ozawa, Tatsuya; Chang, Maria; Chan, Timothy A.; Beal, Kathryn; Bishop, Andrew J.; Barker, Christopher A.; Jones, Terreia S.; Hentschel, Bettina; Gorlia, Thierry; Schlegel, Uwe; Stupp, Roger; Weller, Michael; Holland, Eric C.; Hambardzumyan, Dolores.

In: Brain, Vol. 139, No. 5, 01.05.2016, p. 1458-1471.

Research output: Research - peer-reviewArticle

Pitter, KL, Tamagno, I, Alikhanyan, K, Hosni-Ahmed, A, Pattwell, SS, Donnola, S, Dai, C, Ozawa, T, Chang, M, Chan, TA, Beal, K, Bishop, AJ, Barker, CA, Jones, TS, Hentschel, B, Gorlia, T, Schlegel, U, Stupp, R, Weller, M, Holland, EC & Hambardzumyan, D 2016, 'Corticosteroids compromise survival in glioblastoma' Brain, vol 139, no. 5, pp. 1458-1471. DOI: 10.1093/brain/aww046
Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S et al. Corticosteroids compromise survival in glioblastoma. Brain. 2016 May 1;139(5):1458-1471. Available from, DOI: 10.1093/brain/aww046
Pitter, Kenneth L. ; Tamagno, Ilaria ; Alikhanyan, Kristina ; Hosni-Ahmed, Amira ; Pattwell, Siobhan S. ; Donnola, Shannon ; Dai, Charles ; Ozawa, Tatsuya ; Chang, Maria ; Chan, Timothy A. ; Beal, Kathryn ; Bishop, Andrew J. ; Barker, Christopher A. ; Jones, Terreia S. ; Hentschel, Bettina ; Gorlia, Thierry ; Schlegel, Uwe ; Stupp, Roger ; Weller, Michael ; Holland, Eric C. ; Hambardzumyan, Dolores. / Corticosteroids compromise survival in glioblastoma. In: Brain. 2016 ; Vol. 139, No. 5. pp. 1458-1471
@article{a9a85f0e494a49f7b6c8d4b02fa2eb35,
title = "Corticosteroids compromise survival in glioblastoma",
abstract = "Glioblastoma is the most common and most aggressive primary brain tumour. Standard of care consists of surgical resection followed by radiotherapy and concomitant and maintenance temozolomide (temozolomide/radiotherapy→temozolomide). Corticosteroids are commonly used perioperatively to control cerebral oedema and are frequently continued throughout subsequent treatment, notably radiotherapy, for amelioration of side effects. The effects of corticosteroids such as dexamethasone on cell growth in glioma models and on patient survival have remained controversial. We performed a retrospective analysis of glioblastoma patient cohorts to determine the prognostic role of steroid administration. A disease-relevant mouse model of glioblastoma was used to characterize the effects of dexamethasone on tumour cell proliferation and death, and to identify gene signatures associated with these effects. A murine anti-VEGFA antibody was used in parallel as an alternative for oedema control. We applied the dexamethasone-induced gene signature to The Cancer Genome Atlas glioblastoma dataset to explore the association of dexamethasone exposure with outcome. Mouse experiments were used to validate the effects of dexamethasone on survival in vivo. Retrospective clinical analyses identified corticosteroid use during radiotherapy as an independent indicator of shorter survival in three independent patient cohorts. A dexamethasone-associated gene expression signature correlated with shorter survival in The Cancer Genome Atlas patient dataset. In glioma-bearing mice, dexamethasone pretreatment decreased tumour cell proliferation without affecting tumour cell viability, but reduced survival when combined with radiotherapy. Conversely, anti-VEGFA antibody decreased proliferation and increased tumour cell death, but did not affect survival when combined with radiotherapy. Clinical and mouse experimental data suggest that corticosteroids may decrease the effectiveness of treatment and shorten survival in glioblastoma. Dexamethasone-induced anti-proliferative effects may confer protection from radiotherapy-and chemotherapy-induced genotoxic stress. This study highlights the importance of identifying alternative agents such as vascular endothelial growth factor antagonists for managing oedema in glioblastoma patients. Beyond the established adverse effect profile of protracted corticosteroid use, this analysis substantiates the request for prudent and restricted use of corticosteroids in glioblastoma.",
keywords = "astrocytoma, CNS tumour: surgical treatment, genetics, glioma, neurooncology",
author = "Pitter, {Kenneth L.} and Ilaria Tamagno and Kristina Alikhanyan and Amira Hosni-Ahmed and Pattwell, {Siobhan S.} and Shannon Donnola and Charles Dai and Tatsuya Ozawa and Maria Chang and Chan, {Timothy A.} and Kathryn Beal and Bishop, {Andrew J.} and Barker, {Christopher A.} and Jones, {Terreia S.} and Bettina Hentschel and Thierry Gorlia and Uwe Schlegel and Roger Stupp and Michael Weller and Holland, {Eric C.} and Dolores Hambardzumyan",
year = "2016",
month = "5",
doi = "10.1093/brain/aww046",
volume = "139",
pages = "1458--1471",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Corticosteroids compromise survival in glioblastoma

AU - Pitter,Kenneth L.

AU - Tamagno,Ilaria

AU - Alikhanyan,Kristina

AU - Hosni-Ahmed,Amira

AU - Pattwell,Siobhan S.

AU - Donnola,Shannon

AU - Dai,Charles

AU - Ozawa,Tatsuya

AU - Chang,Maria

AU - Chan,Timothy A.

AU - Beal,Kathryn

AU - Bishop,Andrew J.

AU - Barker,Christopher A.

AU - Jones,Terreia S.

AU - Hentschel,Bettina

AU - Gorlia,Thierry

AU - Schlegel,Uwe

AU - Stupp,Roger

AU - Weller,Michael

AU - Holland,Eric C.

AU - Hambardzumyan,Dolores

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Glioblastoma is the most common and most aggressive primary brain tumour. Standard of care consists of surgical resection followed by radiotherapy and concomitant and maintenance temozolomide (temozolomide/radiotherapy→temozolomide). Corticosteroids are commonly used perioperatively to control cerebral oedema and are frequently continued throughout subsequent treatment, notably radiotherapy, for amelioration of side effects. The effects of corticosteroids such as dexamethasone on cell growth in glioma models and on patient survival have remained controversial. We performed a retrospective analysis of glioblastoma patient cohorts to determine the prognostic role of steroid administration. A disease-relevant mouse model of glioblastoma was used to characterize the effects of dexamethasone on tumour cell proliferation and death, and to identify gene signatures associated with these effects. A murine anti-VEGFA antibody was used in parallel as an alternative for oedema control. We applied the dexamethasone-induced gene signature to The Cancer Genome Atlas glioblastoma dataset to explore the association of dexamethasone exposure with outcome. Mouse experiments were used to validate the effects of dexamethasone on survival in vivo. Retrospective clinical analyses identified corticosteroid use during radiotherapy as an independent indicator of shorter survival in three independent patient cohorts. A dexamethasone-associated gene expression signature correlated with shorter survival in The Cancer Genome Atlas patient dataset. In glioma-bearing mice, dexamethasone pretreatment decreased tumour cell proliferation without affecting tumour cell viability, but reduced survival when combined with radiotherapy. Conversely, anti-VEGFA antibody decreased proliferation and increased tumour cell death, but did not affect survival when combined with radiotherapy. Clinical and mouse experimental data suggest that corticosteroids may decrease the effectiveness of treatment and shorten survival in glioblastoma. Dexamethasone-induced anti-proliferative effects may confer protection from radiotherapy-and chemotherapy-induced genotoxic stress. This study highlights the importance of identifying alternative agents such as vascular endothelial growth factor antagonists for managing oedema in glioblastoma patients. Beyond the established adverse effect profile of protracted corticosteroid use, this analysis substantiates the request for prudent and restricted use of corticosteroids in glioblastoma.

AB - Glioblastoma is the most common and most aggressive primary brain tumour. Standard of care consists of surgical resection followed by radiotherapy and concomitant and maintenance temozolomide (temozolomide/radiotherapy→temozolomide). Corticosteroids are commonly used perioperatively to control cerebral oedema and are frequently continued throughout subsequent treatment, notably radiotherapy, for amelioration of side effects. The effects of corticosteroids such as dexamethasone on cell growth in glioma models and on patient survival have remained controversial. We performed a retrospective analysis of glioblastoma patient cohorts to determine the prognostic role of steroid administration. A disease-relevant mouse model of glioblastoma was used to characterize the effects of dexamethasone on tumour cell proliferation and death, and to identify gene signatures associated with these effects. A murine anti-VEGFA antibody was used in parallel as an alternative for oedema control. We applied the dexamethasone-induced gene signature to The Cancer Genome Atlas glioblastoma dataset to explore the association of dexamethasone exposure with outcome. Mouse experiments were used to validate the effects of dexamethasone on survival in vivo. Retrospective clinical analyses identified corticosteroid use during radiotherapy as an independent indicator of shorter survival in three independent patient cohorts. A dexamethasone-associated gene expression signature correlated with shorter survival in The Cancer Genome Atlas patient dataset. In glioma-bearing mice, dexamethasone pretreatment decreased tumour cell proliferation without affecting tumour cell viability, but reduced survival when combined with radiotherapy. Conversely, anti-VEGFA antibody decreased proliferation and increased tumour cell death, but did not affect survival when combined with radiotherapy. Clinical and mouse experimental data suggest that corticosteroids may decrease the effectiveness of treatment and shorten survival in glioblastoma. Dexamethasone-induced anti-proliferative effects may confer protection from radiotherapy-and chemotherapy-induced genotoxic stress. This study highlights the importance of identifying alternative agents such as vascular endothelial growth factor antagonists for managing oedema in glioblastoma patients. Beyond the established adverse effect profile of protracted corticosteroid use, this analysis substantiates the request for prudent and restricted use of corticosteroids in glioblastoma.

KW - astrocytoma

KW - CNS tumour: surgical treatment

KW - genetics

KW - glioma

KW - neurooncology

UR - http://www.scopus.com/inward/record.url?scp=84966560449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966560449&partnerID=8YFLogxK

U2 - 10.1093/brain/aww046

DO - 10.1093/brain/aww046

M3 - Article

VL - 139

SP - 1458

EP - 1471

JO - Brain

T2 - Brain

JF - Brain

SN - 0006-8950

IS - 5

ER -